Author: Newsdesk

Posted on

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

PR Newswire

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants

SEATTLE, June 12, 2026 /PRNewswire/ — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of its previously announced registered direct offering of 1,363,637 shares (the “Shares”) of its common stock, par value $0.18 per share (“Common Stock”) (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,363,637 shares of Common Stock and short-term Series B warrants to purchase up to 1,363,637 shares of Common Stock (such warrants, collectively, the “Series Warrants”) and accompanying Series Warrants. The Series Warrants are exercisable six months following the date of issuance. The Series A warrants expire on the five and one-half (5.5) year anniversary of the date of issuance. The short-term Series B warrants expire on the two (2) year anniversary of the date of issuance.

(PRNewsfoto/Atossa Therapeutics Inc)

Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $4.5 million before deducting the placement agent’s fees and other estimated offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Series Warrants, if fully exercised on a cash basis, will be approximately $12 million. No assurance can be given that any of the Series Warrants will be exercised, or that the Company will receive cash proceeds from the exercise of the Series Warrants. The Company currently intends to use the net proceeds from the offering for clinical development of its product candidates, working capital and general corporate purposes.

The securities described above were offered and sold by the Company in a registered direct offering pursuant to a “shelf” registration statement on Form S-3 (File No. 333-279367) that was filed with the Securities and Exchange Commission (the “SEC”), on May 13, 2024, and declared effective by the SEC on May 23, 2024. The securities offered in the registered direct offering were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying base prospectus relating to the registered direct offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement and the accompanying base prospectus may also be obtained from Rodman & Renshaw LLC at 600 Lexington Avenue, 32nd Floor, New York, NY 10022, by telephone at (212) 540-4414, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of significant unmet need. The Company’s lead product candidate, (Z)-endoxifen, is currently in development across several clinical settings. More information is available at https://atossatherapeutics.com.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Private Litigation Reform Act of 1995, including but not limited to, the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering, and the intended use of proceeds therefrom. Words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “design,” “predict,” “future,” or other similar expressions or statements regarding intent, belief or current expectations, are forward-looking statements.

Forward-looking statements in this press release, including those regarding the expected closing date of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, the potential exercise of the Series Warrants and potential proceeds therefrom, are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes to differ materially from those projected or anticipated, including, without limitation, risks and uncertainties associated with: market and other conditions, our ability to successfully execute our strategy to shorten our clinical development timelines and pursue a Duchenne Muscular Dystrophy or McCune-Albright Syndrome indication, or other indications for our lead program, (Z)-endoxifen; expected timing, completion and results of our preclinical studies, clinical trials and research and development programs; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; the outcome or timing of necessary regulatory approvals; our ability to maintain compliance with Nasdaq listing requirements; our ability to establish and maintain intellectual property rights covering our products; the impact of general macroeconomic conditions on our business; our ability to raise capital; and other risks and uncertainties detailed from time to time in Atossa’s filings with the SEC, including, without limitation, its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/atossa-therapeutics-announces-closing-of-registered-direct-offering-of-up-to-16-5-million-in-gross-proceeds-302799448.html

SOURCE Atossa Therapeutics Inc

Posted on

Traws Pharma Provides Regulatory Update on Influenza Program

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) — Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).

“Tivoxavir marboxil demonstrated potent efficacy in three animal models of highly pathogenic avian influenza and a pharmacokinetic profile consistent with its use for bird flu treatment and prevention,” said C. David Pauza, PhD Chief Science Officer for Traws Pharma, “The product candidate retains potential for emergency use in a bird flu outbreak and for prevention in high-risk populations.” The Company has a portfolio of back-up influenza antiviral compounds and is actively advancing candidates with TXM’s long-duration pharmacokinetic and antiviral profile and devoid of any mutagenic potential.

“Influenza, including bird flu, continues to be a major public health threat in the US and worldwide,” commented Robert R. Redfield, MD, Chief Medical Officer for Traws Pharma and former Head of the U.S. Centers for Disease Control and Prevention. “While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority. Influenza treatment and prevention is especially important for vulnerable populations including elderly and immunocompromised individuals who are at much greater risk for severe influenza compared to the general population.

“We remain committed to advancing long-acting influenza antivirals and continue to believe this modality has meaningful potential in seasonal influenza prophylaxis. While the recent regulatory feedback affects the timing of our planned challenge study, it does not change our conviction in the underlying scientific rationale. With our cash runway extending to Q1 2027, we are advancing alternative candidates designed to preserve TXM’s pharmacokinetics and efficacy, and exclude potential regulatory concerns,” said Iain Dukes, MA, DPhil, Chief Executive Officer for Traws Pharma.

About Traws Pharma, Inc.

Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health including seasonal influenza and H5N1 bird flu, negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, Lassa Fever and COVID-19/Long COVID.

For more information, please visit www.trawspharma.com and follow us on LinkedIn.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, market size, benefits, effectiveness, safety, and the clinical and regulatory plans for tivoxavir marboxil and ratutrelvir and other investigational antiviral agents, as well as plans for its legacy programs. The Company has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the outcome of Traws’ IND filing with the FDA for tivoxavir marboxil, including the current FDA clinical hold; the success and timing of Traws’ clinical trials; Traws’ ability to identify and advance potential clinical candidates for the treatment of Hantavirus infections, Ebola Virus Disease, Lassa Fever, the potential efficacy of ratutrelvir for the treatment of COVID-19, including the potential to reduce the risk of COVID rebound and Long COVID; the potential for tivoxavir marboxil and ratutrelvir and other investigational antiviral agents to gain market acceptance, if and when regulatory approval is obtained, or to become the new standard of care; Traws’ interactions with the FDA, BARDA, CDC, NAFDAC, AMA and similar foreign regulators; collaborations; market conditions; regulatory requirements and pathways for approval; the ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for Long COVID; the extent of the spread and threat of pandemic flu including H5N1 bird flu; the Company’s cash projections; Traws’ ability to raise additional capital when needed; and those discussed under the heading “Risk Factors” in Traws’ filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.

Traws Pharma Contact:

Charles Parker
Traws Pharma, Inc.
[email protected]
www.trawspharma.com

Investor Contact:

John Fraunces
LifeSci Advisors, LLC
917-355-2395
[email protected]



Posted on

Gencor Releases Second Quarter Fiscal 2026 Results

ORLANDO, Fla., June 12, 2026 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended March 31, 2026 was $33,799,000 compared with $38,204,000 net revenue for the quarter ended March 31, 2025. The decrease in net revenue was primarily due to lower contract equipment revenues recognized over time and associated freight revenue, which resulted from the timing of orders and shipments. As a percentage of net revenue, gross profit margins increased 200 basis points to 31.7% in the quarter ended March 31, 2026, compared to 29.7% in the quarter ended March 31, 2025.

Product engineering and development expenses decreased $52,000 to $629,000 for the quarter ended March 31, 2026, as compared to $681,000 for the quarter ended March 31, 2025 primarily due to lower headcount. Selling, general and administrative (“SG&A”) expenses increased $1,651,000 to $5,843,000 for the quarter ended March 31, 2026, compared to $4,192,000 for the quarter ended March 31, 2025 due to increased trade show expenses. In the quarter ended March 31, 2026 Gencor incurred trade show expenses of $3,525,000 compared with $345,000 in the quarter ended March 31, 2025.

Operating income decreased 34.6%, or $2,244,000, from $6,480,000 for the quarter ended March 31, 2025 compared with $4,236,000 for the quarter ended March 31, 2026, due to higher trade show expenses, which increased by $3,180,000 for the quarter ended March 31, 2026, compared to the quarter ended March 31, 2025. Operating margin was 12.5% for the quarter ended March 31, 2026 compared with 17.0% for the quarter ended March 31, 2025.

For the quarter ended March 31, 2026, the Company had net other income of $937,000, compared to $1,756,000 for the quarter ended March 31, 2025. Interest and dividend income, net of fees, was $1,111,000 in the quarter ended March 31, 2026 as compared to $1,158,000 in the quarter ended March 31, 2025. The net realized and unrealized losses on marketable securities were $174,000 for the quarter ended March 31, 2026, compared to net realized and unrealized gains of $598,000 for the quarter ended March 31, 2025. The decline in net realized and unrealized gains was due to higher interest rates on longer duration bonds that caused a decline in value.

The effective income tax rate for both the quarters ended March 31, 2026 and March 31, 2025 was 26% based on the expected annual effective income tax rate. Net income for the quarter ended March 31, 2026 decreased $2,252,000 or 37.0% to $3,843,000, or $0.26 basic and diluted net income per common share, from $6,095,000, or $0.42 basic and diluted net income per common share, for the quarter ended March 31, 2025. The lower net income resulted primarily from the impact of higher trade show expenses, lower net revenues and net non-operating income, partially offset by improved gross margins.

For the six months ended March 31, 2026 the Company had net revenue of $57,376,000 and net income of $7,285,000, or $0.50 per basic and diluted common share, compared to net revenue of $69,620,000 and net income of $9,912,000 or $0.68 per basic and diluted common share for the six months ended March 31, 2025. The decline in net income on earnings per share was largely due to the increased trade show expenses in the quarter ending March 31, 2026.

At March 31, 2026, the Company had $155.1 million of cash and cash equivalents and marketable securities compared to $136.3 million at September 30, 2025. Net working capital was $205.2 million at March 31, 2026 compared to $197.7 million at September 30, 2025. The Company had no short-term or long-term debt outstanding at March 31, 2026.

The Company’s backlog was $60.5 million at March 31, 2026 compared to $27.8 million at March 31, 2025.

Marc Elliott, Gencor’s President and Chairman of the Board, commented, “Gencor’s second quarter revenue decline from the previous year was due to a slow start to the season delaying asphalt plant orders typically sold earlier in the fiscal year. Despite lower revenue, gross profit margins exceeded expectations, reflecting strong manufacturing execution and effective cost management. Our $60.5 million backlog was more than double the prior year as remaining IIJA funding obligations continued to flow to states. With this record backlog entering the third quarter, we are well-positioned for sustainable performance through the remainder of this fiscal year and into fiscal 2027.”

Gencor Industries, Inc. is a diversified heavy machinery manufacturer for the production of highway construction materials and equipment and environmental control machinery and equipment used in a variety of applications.

   
GENCOR INDUSTRIES, INC.

Condensed Consolidated Income Statements


 (Unaudited)
   
  For the Quarters Ended

March 31,


 		  For the Six Months Ended

March 31,
    2026       2025       2026       2025  
                     
Net revenue $ 33,799,000     $ 38,204,000     $ 57,376,000     $ 69,620,000  
Cost of goods sold   23,091,000       26,851,000       39,913,000       49,599,000  
Gross profit   10,708,000       11,353,000       17,463,000       20,021,000  
                     
Operating expenses:                    
Product engineering and development   629,000       681,000       1,387,000       1,357,000  
Selling, general and administrative   5,843,000       4,192,000       8,739,000       7,560,000  
Total operating expenses   6,472,000       4,873,000       10,126,000       8,917,000  
                     
Operating income   4,236,000       6,480,000       7,337,000       11,104,000  
                     
Other income (expense), net:                    
Interest and dividend income, net of fees   1,111,000       1,158,000       2,288,000       2,147,000  
Net realized and unrealized gains (losses) on marketable securities   (174,000 )     598,000       199,000       143,000  
                     
Total other income, net   937,000       1,756,000       2,487,000       2,290,000  
                     
Income before income tax expense   5,173,000       8,236,000       9,824,000       13,394,000  
Income tax expense   1,330,000       2,141,000       2,539,000       3,482,000  
Net income $ 3,843,000     $ 6,095,000     $ 7,285,000     $ 9,912,000  
                     
Net income per common share – basic and diluted $ 0.26     $ 0.42     $ 0.50     $ 0.68  
                     

   
GENCOR INDUSTRIES, INC.

Condensed Consolidated Balance Sheets
   
ASSETS March 31, 2026


(Unaudited)



 		  September 30, 2025
Current assets:          
Cash and cash equivalents $ 43,464,000     $ 26,587,000  
Marketable securities at fair value (cost of $109,533,000 at March 31, 2026 and $107,237,000 at September 30, 2025)   111,670,000       109,714,000  
Accounts receivable, less allowance for credit losses of $529,000 at March 31, 2026 and $434,000 at September 30, 2025   3,932,000       3,130,000  
Contract assets   7,552,000       12,208,000  
Inventories, net   51,071,000       53,503,000  
Prepaid expenses and other current assets   3,167,000       1,399,000  
Total current assets   220,856,000       206,541,000  
Property and equipment, net   11,154,000       11,079,000  
Deferred income taxes   4,843,000       4,584,000  
Other long-term assets   209,000       392,000  
Total Assets $ 237,062,000     $ 222,596,000  
               
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable $ 4,834,000     $ 1,842,000  
Customer deposits   7,105,000       3,889,000  
Contract liabilities   1,233,000       –  
Accrued expenses   2,282,000       2,741,000  
Current operating lease liabilities   156,000       339,000  
Total current liabilities   15,610,000       8,811,000  
           
Unrecognized tax benefits   2,365,000       1,983,000  
Total liabilities   17,975,000       10,794,000  
Commitments and contingencies          
Shareholders’ equity:          
Preferred stock, par value $.10 per share; 300,000 shares authorized; none issued   –        
Common stock, par value $.10 per share; 15,000,000 shares authorized; 12,339,000 shares issued and outstanding at March 31, 2026 and September 30, 2025   1,234,000       1,234,000  
Class B Stock, par value $.10 per share; 6,000,000 shares authorized; 2,319,000 shares issued and outstanding at March 31, 2026 and September 30, 2025   232,000       232,000  
Capital in excess of par value   12,590,000       12,590,000  
Retained earnings   205,031,000       197,746,000  
Total shareholders’ equity   219,087,000       211,802,000  
Total Liabilities and Shareholders’ Equity $ 237,062,000     $ 222,596,000  


Caution Concerning Forward Looking Statements – This press release and our other communications and statements may contain certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements about the Company’s beliefs, plans, objectives, goals, expectations, estimates, projections and intentions. These statements are subject to significant risks and uncertainties and are subject to change based on various factors, many of which are beyond the Company’s control. The Company’s actual results may differ materially from those set forth in the Company’s forward-looking statements depending on a variety of important factors, including the financial condition of the Company’s customers, changes in the economic and competitive environments, and demand for the Company’s products. In addition, the impact of (i) the United States (“U.S.”) government’s tariff announcements, (ii) the ongoing conflicts and/or tensions involving Russia, Ukraine, Israel, Iran, the U.S., and various other countries, and (iii) any actions taken by the U.S. or other countries in response to such tariff announcements, conflicts and/or tensions, could result in a disruption in our supply chain and higher costs of our products. The words “may,” “could,” “should,” “would,” “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “target,” “goal,” and similar expressions are intended to identify forward-looking statements.

For information concerning these factors and related matters, see the following sections of the Company’s Annual Report on Form 10-K for the year ended September 30, 2025: (a) Part I, Item 1A, “Risk Factors” and (b) Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. However, other factors besides those referenced could adversely affect the Company’s results, and you should not consider any such list of factors to be a complete set of all potential risks or uncertainties. Any forward-looking statements made by the Company herein speak as of the date of this press release. The Company does not undertake to update any forward-looking statements, except as required by law.

Unless the context otherwise indicates, all references in this press release to the “Company,” “Gencor,” “we,” “us,” or “our,” or similar words are to Gencor Industries, Inc. and its subsidiaries.

Contact: Raymond Cole, Interim Chief Financial Officer
  407-290-6000
   



Posted on

Heartland Express, Inc. Declares Regular Quarterly Dividend

NORTH LIBERTY, Iowa, June 12, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on July 6, 2026, to shareholders of record at the close of business on June 23, 2026. We currently estimate that a total of $1.6 million will be paid on the Company’s approximate seventy-eight million shares of common stock. This is the Company’s ninety-second consecutive quarterly cash dividend. With the payment of this dividend, the Company will have paid a total of $564.5 million in cash dividends, including four special dividends since the dividend program was implemented in the third quarter of 2003.

The press release may contain forward-looking statements, which are based on information currently available. These statements and assumptions involve certain risks and uncertainties. Actual events may differ from these expectations as specified from time to time in filings with the Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statement to the extent it becomes aware that it will not be achieved for any reason.

For further information contact
Michael J. Gerdin, CEO
Christopher A. Strain, CFO
Heartland Express, Inc.
319-645-7060



Posted on

BlackRock Announces Product Updates

BlackRock Announces Product Updates

NEW YORK–(BUSINESS WIRE)–
BlackRock has one of the most comprehensive investment platforms in the industry, providing investors with choice to meet their individual needs. Investors continue to turn to BlackRock to unlock the full potential of their portfolios, as evidenced by nearly $2 trillion of net inflows in the past five years globally.1

As we evolve our global investment platform, we also continually assess how our funds are meeting investors’ investment objectives and the needs of our clients. As a result of that exercise, and reflecting evolving investor demand, BlackRock is announcing the upcoming liquidation of 19 U.S.-domiciled mutual funds and ETFs. In the U.S., BlackRock offers nearly 700 mutual funds and ETFs for investors to access different market exposures, including more than 30 products launched in the past year.2

BlackRock has also built one of the industry’s widest ranges of sustainable and transition investment strategies, representing $1.3 trillion in client AUM3 across a global suite of more than 500 products.4 In the last three years, clients have entrusted BlackRock with approximately $185 billion in net inflows in sustainable and transition investing, including around $60 billion last year.5

Fund Name

Last Trading Date

Liquidation Date

BlackRock LifePath ESG Index Retirement Fund

N/A

10/16/2026

BlackRock LifePath ESG Index 2030

N/A

10/16/2026

BlackRock LifePath ESG Index 2035

N/A

10/16/2026

BlackRock LifePath ESG Index 2040

N/A

10/16/2026

BlackRock LifePath ESG Index 2045

N/A

10/16/2026

BlackRock LifePath ESG Index 2050

N/A

10/16/2026

BlackRock LifePath ESG Index 2055

N/A

10/16/2026

BlackRock LifePath ESG Index 2060

N/A

10/16/2026

BlackRock LifePath ESG Index 2065

N/A

10/16/2026

BlackRock LifePath ESG Index 2070

N/A

10/16/2026

BlackRock Sustainable Aware Advantage International Equity Fund

N/A

09/11/2026

iShares ESG Aware 80/20 Aggressive Allocation ETF (CBOE: EAOA)

08/12/2026

08/17/2026

iShares ESG Aware 30/70 Conservative Allocation ETF (CBOE: EAOK)

08/12/2026

08/17/2026

iShares ESG Aware 40/60 Moderate Allocation ETF (CBOE: EAOM)

08/12/2026

08/17/2026

iShares ESG Aware 60/40 Balanced Allocation ETF (CBOE: EAOR)

08/12/2026

08/17/2026

iShares Future Metaverse Tech and Communications ETF (NYSE: IVRS)

08/12/2026

08/17/2026

iShares Interest Rate Hedged U.S. Aggregate Bond ETF (NYSE: AGRH)

08/12/2026

08/17/2026

iShares U.S. Consumer Focused ETF (NYSE: IEDI)

08/12/2026

08/17/2026

iShares U.S. Select Equity Active ETF (NASDAQ: BELT)

08/12/2026

08/17/2026

As disclosed in the prospectuses, investors will incur management fees until the liquidations are complete. In addition to the management fee, investors who opt to sell an ETF will bear the usual transaction and commissions costs in the secondary market. In both cases, investors may see a capital gain or loss on their investment.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate | Twitter: @blackrock | LinkedIn: www.linkedin.com/company/blackrock

About iShares

iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of more than 1,700 exchange traded funds (ETFs) and approximately $5.5 trillion in assets under management as of March 31, 2026, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.

Carefully consider the Funds’ investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the Funds’ prospectuses or, if available, the summary prospectuses which may be obtained by visiting www.iShares.com or www.blackrock.com. Read the prospectus carefully before investing.

Investing involves risk, including possible loss of principal.

Transactions in shares of ETFs may result in brokerage commissions and may generate tax consequences. All regulated investment companies are obliged to distribute portfolio gains to shareholders. This material does not constitute any specific legal, tax or accounting advice. Please consult with qualified professionals for this type of advice.

This information should not be relied upon as research, investment advice, or a recommendation regarding any products, strategies, or any security in particular. This material is strictly for illustrative, educational, or informational purposes and is subject to change.

The Funds are distributed by BlackRock Investments, LLC (together with its affiliates, “BlackRock”).

© 2026 BlackRock, Inc. or its affiliates. All Rights Reserved. BLACKROCK and iSHARES are trademarks of BlackRock, Inc. or its affiliates. All other trademarks are those of their respective owners.

____________________

1 BlackRock, as of May 2026.

2 BlackRock, as of March 2026.

3 Morningstar Global Sustainable fund flows, as of Q4 2025. Covers assets as defined by Morningstar to have a sustainability focus. BlackRock (including iShares) has the largest global sustainable fund assets across actively and passively managed funds.

4 BlackRock as of December 2025. This includes some transition focused strategies that also meet our Sustainable Investing Criteria (Screened, Uplift, Thematic, and Impact strategies using environmental, social and/or governance data as a portfolio construction input and a subset also seek to achieve long term sustainability outcomes in line with each specific investment objective).

5 BlackRock as of December 2025. This includes some transition-focused strategies that also meet our Sustainable Investing Platform criteria (Screened, Uplift, Thematic, and Impact strategies using environmental, social and/or governance data as a portfolio construction input and a subset also seek to achieve long-term sustainability outcomes in line with each specific investment objective).

 

Media:


Joanna Yau

[email protected]

646-856-7274

Catherine Sperl

[email protected]

646-951-1599

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Logo
Logo
Posted on

TechCreate Group Ltd. Issues Statement Addressing NYSE Delisting Procedure

TechCreate Group Ltd. Issues Statement Addressing NYSE Delisting Procedure

SINGAPORE–(BUSINESS WIRE)–TechCreate Group Ltd. (NYSE American: TCGL) (“TechCreate” or the “Company”), a technology consultancy and advanced software solutions provider specializing in payment solutions, cybersecurity, and digital services, provided a statement in light of NYSE American LLC’s (“NYSE American”) announcement that it intends to commence proceedings to delist TechCreate’s Class A ordinary shares from the NYSE American stock exchange and, in the interim, to continue to suspend the Company’s shares from trading.

Following the NYSE Regulation’s June 11, 2026 notice to the Company regarding the intended delisting, the Company has and will continue to consult with its legal counsel and other advisors to evaluate its options, including the viability of an appeal and any further necessary actions.

NYSE American cited the “other event” provision of Section 1002(e) of the NYSE American Company Guide (the “Guide”), as well as Sections 1001 and 1003 of the Guide, in support of its decision that the Company’s stock is purportedly unsuitable for continued trading on the exchange. To date, NYSE Regulation has not claimed or communicated any wrongdoing by the Company, whether in regard to NYSE’s investigation of the recent trading activity of the Company’s stock or otherwise. NYSE American’s decision does not affect the Company’s operations or financial position, and the Company continues to conduct business in the ordinary course.

About TechCreate Group Ltd.

TechCreate Group Ltd. is a Singapore-based payment software solutions provider. Founded in 2015, the Company delivers digital payment and infrastructure solutions to financial institutions, telecommunications, deposit insurance, and enterprises. TechCreate’s offerings include real-time payment systems, digital banking platforms, API management, cybersecurity, and cloud computing. Its proprietary Artificial Intelligence Real-Time Engine (AI-RTE) is designed to enable fast, secure, and efficient payment processing. For more information, visit https://www.techcreate.com.sg/.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and TechCreate Group Ltd. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Relations
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

KEYWORDS: Singapore Southeast Asia Asia Pacific

INDUSTRY KEYWORDS: Technology Payments Consulting Security Professional Services Digital Cash Management/Digital Assets Software Internet Artificial Intelligence

MEDIA:

Logo
Logo
Posted on

Federal Signal Provides Update on Streator, Illinois Facility; Announces Signing of Definitive Agreement to Acquire Western Technology, Expanding its Presence in Portable Industrial Signaling Solutions for Hazardous Environments

PR Newswire

DOWNERS GROVE, Ill., June 12, 2026 /PRNewswire/ — Federal Signal Corporation (NYSE: FSS) (the “Company”), a leader in environmental and safety solutions, today provided an update on its manufacturing facility in Streator, Illinois following a tornado that impacted the area on June 11, 2026.

Initial assessments indicate that the facility sustained no structural damage and all employees are safe, with no reported injuries. The Company continues to evaluate conditions, but operations at the facility are ongoing with no material disruption to production.

“The safety of our employees and the broader Streator community is our current priority,” said Jennifer L. Sherman, President and Chief Executive Officer. “We are deeply relieved that our team members and facility came through this event unharmed. Our thoughts are with everyone in Streator who have been impacted by this storm.”

The Company is closely monitoring the situation in the surrounding community and will be reaching out to local leaders and organizations to identify ways to support recovery efforts.

The Company also announced the signing of a definitive agreement to acquire certain assets and operations of Western Technology, Inc. (“Western Technology”).

Based in Bremerton, Washington, Western Technology is a manufacturer of proprietary portable explosion-protected lighting solutions for mission-critical applications, serving end-customers across industrial processing, petrochemical, and aerospace and defense industries, where regulatory compliance, reliability, and safety are paramount.

Over the last twelve months, Western Technology generated revenues of approximately $6 million.

“Over the last several years, the organic investments we have made to structurally strengthen our Safety and Security Systems Group have set the stage for future profitable growth, inclusive of M&A. On that note, we are thrilled to announce Western Technology as our first acquisition as we begin to execute on our inorganic growth pipeline within our Safety and Security Systems Group,” said Sherman.

“The acquisition broadens our industrial signaling equipment portfolio by expanding into the portable explosion-protected lighting solutions market for hazardous applications, where Western Technology has built a niche market-leading position. As we integrate Western Technology, we are excited to leverage the power of our platform to drive synergies spanning sales channel alignment to enhance the reach of Western Technology’s products, operational efficiency improvements leveraging our existing U.S. manufacturing operations, and new product development.”

The transaction is expected to close in the next 90 days, subject to customary closing conditions.

About Federal Signal
Federal Signal Corporation (NYSE: FSS) builds and delivers equipment of unmatched quality that moves material, cleans infrastructure, and protects the communities where we work and live. Founded in 1901, Federal Signal is a leading global designer, manufacturer and supplier of products and total solutions that serve municipal, governmental, industrial and commercial customers. Headquartered in Downers Grove, Ill., with manufacturing facilities worldwide, the Company operates two groups: Environmental Solutions and Safety and Security Systems. For more information on Federal Signal, visit: www.federalsignal.com.

“
Safe Harbor
”
Statement under the Private Securities Litigation Reform Act of 1995
This release contains unaudited financial information and various forward-looking statements as of the date hereof and we undertake no obligation to update these forward-looking statements regardless of new developments or otherwise. Statements in this release that are not historical are forward-looking statements. Forward-looking statements should not be relied upon as a predictor of actual results. Such statements are subject to various risks and uncertainties that could cause actual results to vary materially from those stated. Such risks and uncertainties include but are not limited to: economic and political uncertainty, risks and adverse economic effects associated with geopolitical conflicts including tariffs and other trade conflicts, legal and regulatory developments, foreign currency exchange rate changes, inflationary pressures, product and price competition, supply chain disruptions, availability and pricing of raw materials, interest rate changes, risks associated with acquisitions such as integration of operations and achieving anticipated revenue and cost benefits, work stoppages, increases in pension funding requirements, cybersecurity risks, increased legal expenses and litigation results and other risks and uncertainties described in filings with the Securities and Exchange Commission.

Cision View original content:https://www.prnewswire.com/news-releases/federal-signal-provides-update-on-streator-illinois-facility-announces-signing-of-definitive-agreement-to-acquire-western-technology-expanding-its-presence-in-portable-industrial-signaling-solutions-for-hazardous-environments-302799441.html

SOURCE Federal Signal Corporation

Posted on

Lotus Tech Announces Operational and Earnings Reporting Updates

  • Lotus Tech is advancing the strategic acquisition of Lotus UK targeted to close in 2026, to unify brand positioning and improve operational efficiency.
  • Comprehensive pre-acquisition and integration planning is in progress to unlock full synergies and support the execution of the Company’s Focus 2030 long-term strategy.
  • The Company temporarily suspends the release of financial results for the first and third quarters in 2026 to prioritize acquisition- related compliance work.

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Lotus Technology Inc. (Nasdaq: LOT) (“Lotus Tech” or the “Company”), a leading global intelligent and luxury mobility provider, today provided an update on recent developments and announced the temporary suspension of the publication of earnings releases for the first quarter and third quarter of fiscal year 2026.

Recent Developments

  • Enhanced Global Presence: On April 3, 2026, Lotus showcased the latest Emira models at the New York International Auto Show, bringing Lotus’ performance legacy to one of North America’s most prominent automotive stages. On April 24, 2026, Lotus unveiled its brand-new Hyper Hybrid SUV Eletre X Black & Gold Limited Edition at Auto China 2026 in Beijing. The dual showcase across key global events underscores Lotus’ strong premium brand influence and broad market recognition worldwide.
  • Eletre Launch in Canada: On April 24, 2026, Eletre officially entered the Canadian market via export, bringing Lotus into the high-performance luxury SUV segment in North America. This milestone reflects the Company’s continued expansion into new segments and markets.
  • Focus 2030: On May 11, 2026, Lotus announced Focus 2030, an evolved business strategy designed to underpin its competitiveness and transformation into a more flexible and sustainable business model ensuring market resilience amid external headwinds.
  • Emira 420 Sport: On May 26, 2026, Lotus introduced the Emira 420 Sport – the most powerful, lightest and most aerodynamically capable Emira to date. It reinforces Lotus’ commitment to preserving its DNA by delivering greater agility, response and driver engagement.

Updates on Strategic Acquisition of Lotus UK & Suspension of the First and Third Financial Report in 2026

Lotus Tech is preparing for and steadily advancing the strategic acquisition of Lotus UK, which is expected to be closed in 2026. The acquisition will enable Lotus Tech and Lotus UK to operate under the One Lotus strategy, maintain a consistent global identity as a high-performance luxury brand, strengthen worldwide recognition, and maximize the heritage of the brand.

Because the transaction is expected to constitute an acquisition under common control, Lotus Tech is working closely with Lotus UK to conduct comprehensive preparations across regulatory filings, SOX compliance, operational system alignment and financial reporting, aiming to ensure a seamless post-acquisition transition. Meanwhile, the Company continues to refine the integration plan to fully capture synergies across R&D, supply chain, administration, etc., driving cost optimization and operational efficiency. These efforts are aligned with the Lotus Focus 2030 strategy, which underpins a transformation toward greater flexibility and sustainability, and strengthens overall competitiveness and market resilience against external headwinds.

In order to prioritize resources for the strategic acquisition of Lotus UK, Lotus Tech is temporarily suspending the release of financial results for the first and third quarters of 2026. Lotus Tech will continue to report its financial results for the first half and full fiscal year of 2026.

Dr. Daxue Wang, Chief Finance Officer of Lotus Tech, said, “Pending the closing of the transaction we are suspending earnings release for Q1 and Q3 of 2026. We are seeing great momentum in the luxury EV strategy and continue to be laser focused on delivering on our growth strategy. The temporary adjustment to our 2026 reporting schedule enables our teams to prioritize the successful execution of the Lotus UK acquisition and integration process. We believe this is an important step in strengthening our global platform and supporting sustainable long-term growth.”

Lotus Tech reaffirms its unwavering commitment to maintaining a high level of transparency for investors and stakeholders and will continue to comply with all applicable U.S. securities laws and Nasdaq listing requirements. This adjustment does not impact the Company’s underlying business operations or financial fundamentals. At the same time, Lotus Tech continues to see encouraging operational momentum across key markets – the recent entry into Canada marks an important step in expanding its North American footprint, reflecting growing demand for premium electric vehicles and a progressively supportive trade and regulatory environment. Building on its global product pipeline and strategic initiatives under Focus 2030, the Company remains confident in its ability to deliver sustained growth and strengthen its financial performance over the long term.

About Lotus Technology Inc.

Lotus Technology Inc. has operations across the UK, the EU and China. The Company is dedicated to delivering luxury lifestyle electric vehicles, with a focus on world-class R&D in next-generation automobility technologies such as electrification, digitalization and more. For more information about Lotus Technology Inc., please visit www.group-lotus.com.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “forecast”, “plan”, “seek”, “future”, “propose” or “continue”, or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology. Forward-looking statements involve inherent risks and uncertainties, including those identified under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and Lotus Technology Inc. undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Contact Information

For investor inquiries
[email protected]



Posted on

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.

This decision was taken following a comprehensive evaluation, the Company determined that maintaining a dual listing on the TSXV does not justify the associated costs and administrative requirements and presents challenges due to the different regulatory environments. It is envisioned that the voluntary delisting will eliminate duplicative exchange fees, reduce legal and accounting expenses, optimize company financing initiatives and minimize regulatory complexity, and enable greater management focus on the advancement of the XRx-026 program for the treatment of gout for long-term shareholder value creation.

All shareholders, including Canadian shareholders, will continue to maintain full trading access of their common shares on Nasdaq. No action is required by shareholders in connection with the voluntary delisting. Shareholders with account-specific questions are encouraged to contact their respective brokers.

The voluntary delisting from the TSXV was approved by the Company’s Board of Directors. In accordance with TSXV policies, shareholder approval is not required as the Company’s common shares are listed on an acceptable alternative market. XORTX will continue to be a reporting issuer under applicable securities laws in Alberta, British Columbia and Ontario.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy and recently acquired VB4-P5 program, which is currently at the pre-IND stage of development and targets both rare and prevalent forms of kidney disease. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

For more information, please contact:

Allen Davidoff, CEO Nick Rigopulos, Director of Communications
[email protected] [email protected]
+1 403 455 7727 +1 617 901 0785
   

Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company’s beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to our ongoing compliance with Nasdaq listing standards; the success and timing of our preclinical studies and clinical trials; our plans to develop and commercialize our product candidates; and our plans to advance research in other kidney disease applications. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC’s website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.



Posted on

Nutrien Cautions Investors Regarding Ocehan LLC’s Below Market “Mini-Tender” Offer

Nutrien Cautions Investors Regarding Ocehan LLC’s Below Market “Mini-Tender” Offer

SASKATOON, Saskatchewan–(BUSINESS WIRE)–
Nutrien Ltd. (TSX and NYSE: NTR) has received notice of an unsolicited “mini-tender” offer made by Ocehan LLC (“Ocehan”) to purchase up to 100,000 Nutrien common shares, or approximately 0.02% of Nutrien’s outstanding shares, at a price of C$70.20 per share. The offering price represents a discount of 24.91% and 26.13%, respectively, to the closing prices of Nutrien shares on the Toronto Stock Exchange and New York Stock Exchange on May 8, 2026, the last trading day before the mini-tender offer was commenced.

Nutrien does not endorse Ocehan’s unsolicited offer, has no association with Ocehan or its offer, and does not recommend or endorse this unsolicited mini-tender offer. Shareholders are cautioned that Ocehan’s offer has been made at a price below the current market price for the shares.

Ocehan has made similar unsolicited mini-tender offers for shares of several other public companies. Mini-tender offers are designed to avoid many of the investor protections like disclosure and procedural protections applicable to most take-over bids and tender offers under Canadian and U.S. securities law. The Canadian Securities Administrators (“CSA”) and the U.S. Securities and Exchange Commission (“SEC”) have expressed concerns about mini-tender offers, including the possibility that investors might tender to such offers without understanding the offer price relative to the actual market price of their securities.

Comments from the CSA on mini-tender offers can be found on the Ontario Securities Commission website at: CSA Staff Notice 61-301 Staff Guidance on the Practice of “Mini-Tenders”. The SEC has noted that “bidders make mini-tender offers at below-market prices, hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC’s advisory to investors can be found at: https://www.sec.gov/about/reports-publications/investorpubsminitend.

Nutrien urges shareholders to obtain current market quotations for their shares, consult with their broker or financial advisor and exercise caution with respect to Ocehan’s offer. Shareholders who have already tendered their shares should consider taking actions to withdraw them, including reviewing the withdrawal procedures in Ocehan’s offering documents.

Nutrien strongly encourages brokers, dealers and other market participants to exercise caution and review the letter regarding broker-dealer mini-tender offer dissemination and disclosures on the SEC website at: Letter to SIA re: Broker-Dealer Mini-Tender Offer Dissemination and Disclosures (sec.gov) and the relevant provisions in the CSA’s notice referenced above. Nutrien requests that a copy of this news release be included with all distributions of materials relating to Ocehan’s mini-tender offer related to Nutrien shares.

About Nutrien

Nutrien is a leading global provider of crop inputs and services. We operate a world-class network of production, distribution and ag retail facilities that positions us to efficiently serve the needs of growers. We focus on creating long-term value by prioritizing investments that strengthen the advantages of our business across the ag value chain and by maintaining access to the resources and the relationships with stakeholders needed to achieve our goals.

FOR FURTHER INFORMATION:

Investor Contact

Jeff Holzman

Senior Vice President, Investor Relations and FP&A

(306) 933 8545 – [email protected]

Media Contact

Simon Scott

Vice President, Global Communications

(403) 225 7213 – [email protected]

Contact us at: www.nutrien.com

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Retail Agriculture Natural Resources Other Retail

MEDIA:

Logo
Logo